Annual EBITDA
-$63.05 M
+$40.60 M+39.17%
December 31, 2023
Summary
- As of February 7, 2025, AUPH annual EBITDA is -$63.05 million, with the most recent change of +$40.60 million (+39.17%) on December 31, 2023.
- During the last 3 years, AUPH annual EBITDA has risen by +$39.87 million (+38.74%).
- AUPH annual EBITDA is now -7214.04% below its all-time high of -$862.00 thousand, reached on December 31, 2002.
Performance
AUPH EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$20.91 M
+$13.39 M+178.07%
September 30, 2024
Summary
- As of February 7, 2025, AUPH quarterly EBITDA is $20.91 million, with the most recent change of +$13.39 million (+178.07%) on September 30, 2024.
- Over the past year, AUPH quarterly EBITDA has increased by +$13.39 million (+178.07%).
- AUPH quarterly EBITDA is now at all-time high.
Performance
AUPH Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$4.39 M
+$27.39 M+119.08%
September 30, 2024
Summary
- As of February 7, 2025, AUPH TTM EBITDA is $4.39 million, with the most recent change of +$27.39 million (+119.08%) on September 30, 2024.
- Over the past year, AUPH TTM EBITDA has increased by +$27.39 million (+119.08%).
- AUPH TTM EBITDA is now -30.39% below its all-time high of $6.31 million, reached on March 31, 2012.
Performance
AUPH TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AUPH EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.2% | +178.1% | +119.1% |
| 3 y3 years | +38.7% | +389.3% | +104.0% |
| 5 y5 years | -15.5% | +389.3% | +104.0% |
AUPH EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +64.5% | at high | +156.4% | at high | +102.5% |
| 5 y | 5-year | at high | +64.5% | at high | +141.7% | at high | +102.5% |
| alltime | all time | -7214.0% | +64.5% | at high | +141.7% | -30.4% | +102.5% |
Aurinia Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $20.91 M(+178.1%) | $4.39 M(-119.1%) |
| Jun 2024 | - | $7.52 M(-293.8%) | -$23.00 M(-41.2%) |
| Mar 2024 | - | -$3.88 M(-80.8%) | -$39.15 M(-31.6%) |
| Dec 2023 | -$63.05 M(-39.2%) | -$20.16 M(+210.7%) | -$57.22 M(-7.8%) |
| Sep 2023 | - | -$6.49 M(-24.8%) | -$62.04 M(-1.2%) |
| Jun 2023 | - | -$8.63 M(-60.7%) | -$62.77 M(-29.3%) |
| Mar 2023 | - | -$21.95 M(-12.1%) | -$88.81 M(-14.5%) |
| Dec 2022 | -$103.65 M(-41.6%) | -$24.97 M(+245.6%) | -$103.91 M(-5.9%) |
| Sep 2022 | - | -$7.23 M(-79.2%) | -$110.38 M(-27.7%) |
| Jun 2022 | - | -$34.67 M(-6.4%) | -$152.74 M(-7.1%) |
| Mar 2022 | - | -$37.04 M(+17.8%) | -$164.36 M(-7.4%) |
| Dec 2021 | -$177.44 M(+72.4%) | -$31.45 M(-36.6%) | -$177.44 M(+15.5%) |
| Sep 2021 | - | -$49.59 M(+7.1%) | -$153.64 M(+5.3%) |
| Jun 2021 | - | -$46.29 M(-7.7%) | -$145.87 M(+15.7%) |
| Mar 2021 | - | -$50.13 M(+555.9%) | -$126.13 M(+25.1%) |
| Dec 2020 | -$102.92 M(+14.6%) | -$7.64 M(-81.7%) | -$100.84 M(-26.3%) |
| Sep 2020 | - | -$41.81 M(+57.5%) | -$136.85 M(+20.4%) |
| Jun 2020 | - | -$26.54 M(+6.8%) | -$113.65 M(+10.8%) |
| Mar 2020 | - | -$24.85 M(-43.1%) | -$102.60 M(+14.3%) |
| Dec 2019 | -$89.77 M(+64.4%) | -$43.65 M(+134.5%) | -$89.77 M(+71.3%) |
| Sep 2019 | - | -$18.61 M(+20.2%) | -$52.40 M(+1.3%) |
| Jun 2019 | - | -$15.49 M(+28.9%) | -$51.72 M(+0.4%) |
| Mar 2019 | - | -$12.02 M(+91.5%) | -$51.53 M(-5.6%) |
| Dec 2018 | -$54.59 M(+19.7%) | -$6.28 M(-65.0%) | -$54.59 M(-9.2%) |
| Sep 2018 | - | -$17.93 M(+17.2%) | -$60.10 M(+8.1%) |
| Jun 2018 | - | -$15.30 M(+1.5%) | -$55.59 M(+11.3%) |
| Mar 2018 | - | -$15.08 M(+28.0%) | -$49.97 M(+9.6%) |
| Dec 2017 | -$45.61 M(+113.8%) | -$11.78 M(-12.3%) | -$45.61 M(+9.9%) |
| Sep 2017 | - | -$13.43 M(+38.7%) | -$41.49 M(+25.4%) |
| Jun 2017 | - | -$9.68 M(-9.7%) | -$33.09 M(+19.9%) |
| Mar 2017 | - | -$10.72 M(+40.0%) | -$27.60 M(+29.4%) |
| Dec 2016 | -$21.34 M(-3.1%) | -$7.66 M(+52.3%) | -$21.34 M(+13.3%) |
| Sep 2016 | - | -$5.03 M(+20.1%) | -$18.84 M(-4.9%) |
| Jun 2016 | - | -$4.19 M(-6.1%) | -$19.80 M(-7.1%) |
| Mar 2016 | - | -$4.46 M(-13.6%) | -$21.30 M(-3.3%) |
| Dec 2015 | -$22.02 M(+23.2%) | -$5.16 M(-13.9%) | -$22.02 M(-10.3%) |
| Sep 2015 | - | -$5.99 M(+5.4%) | -$24.56 M(+78.6%) |
| Jun 2015 | - | -$5.69 M(+9.9%) | -$13.75 M(-26.6%) |
| Mar 2015 | - | -$5.18 M(-32.7%) | -$18.73 M(+4.5%) |
| Dec 2014 | -$17.87 M(+217.0%) | -$7.70 M(-259.9%) | -$17.93 M(+58.5%) |
| Sep 2014 | - | $4.81 M(-145.1%) | -$11.31 M(-40.9%) |
| Jun 2014 | - | -$10.66 M(+143.7%) | -$19.13 M(+105.0%) |
| Mar 2014 | - | -$4.38 M(+306.3%) | -$9.34 M(+65.6%) |
| Dec 2013 | -$5.64 M(-36.1%) | -$1.08 M(-64.3%) | -$5.64 M(-40.7%) |
| Sep 2013 | - | -$3.02 M(+248.3%) | -$9.50 M(+19.2%) |
| Jun 2013 | - | -$866.00 K(+27.5%) | -$7.97 M(-13.3%) |
| Mar 2013 | - | -$679.00 K(-86.3%) | -$9.20 M(+5.0%) |
| Dec 2012 | -$8.83 M(+510.8%) | -$4.94 M(+232.5%) | -$8.76 M(+475.1%) |
| Sep 2012 | - | -$1.49 M(-29.0%) | -$1.52 M(+66.6%) |
| Jun 2012 | - | -$2.09 M(+773.6%) | -$914.20 K(-114.5%) |
| Mar 2012 | - | -$239.50 K(-110.4%) | $6.31 M(+26.2%) |
| Dec 2011 | -$1.45 M | $2.29 M(-361.6%) | $5.00 M(+832.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2011 | - | -$876.90 K(-117.1%) | $536.10 K(+110.9%) |
| Jun 2011 | - | $5.13 M(-431.0%) | $254.20 K(-105.0%) |
| Mar 2011 | - | -$1.55 M(-28.5%) | -$5.07 M(+20.3%) |
| Dec 2010 | -$4.23 M(-32.8%) | -$2.17 M(+86.9%) | -$4.22 M(+240.2%) |
| Sep 2010 | - | -$1.16 M(+478.8%) | -$1.24 M(-26.0%) |
| Jun 2010 | - | -$200.20 K(-71.1%) | -$1.67 M(-55.5%) |
| Mar 2010 | - | -$691.60 K(-185.3%) | -$3.76 M(-32.3%) |
| Dec 2009 | -$6.28 M(-55.8%) | $811.10 K(-150.9%) | -$5.56 M(-23.5%) |
| Sep 2009 | - | -$1.59 M(-30.3%) | -$7.27 M(-20.4%) |
| Jun 2009 | - | -$2.29 M(-8.1%) | -$9.13 M(-24.3%) |
| Mar 2009 | - | -$2.49 M(+176.8%) | -$12.06 M(-16.3%) |
| Dec 2008 | -$14.22 M(-58.3%) | -$898.40 K(-74.0%) | -$14.42 M(-33.2%) |
| Sep 2008 | - | -$3.46 M(-33.8%) | -$21.60 M(-16.7%) |
| Jun 2008 | - | -$5.22 M(+7.8%) | -$25.92 M(-13.9%) |
| Mar 2008 | - | -$4.84 M(-40.0%) | -$30.10 M(-5.8%) |
| Dec 2007 | -$34.12 M(+51.0%) | -$8.08 M(+3.8%) | -$31.95 M(+7.6%) |
| Sep 2007 | - | -$7.78 M(-17.3%) | -$29.69 M(+5.6%) |
| Jun 2007 | - | -$9.40 M(+40.3%) | -$28.11 M(+14.6%) |
| Mar 2007 | - | -$6.70 M(+15.4%) | -$24.52 M(+9.8%) |
| Dec 2006 | -$22.60 M(-19.7%) | -$5.81 M(-6.3%) | -$22.33 M(-6.7%) |
| Sep 2006 | - | -$6.20 M(+6.7%) | -$23.94 M(-1.1%) |
| Jun 2006 | - | -$5.81 M(+28.6%) | -$24.20 M(-3.1%) |
| Mar 2006 | - | -$4.52 M(-39.0%) | -$24.97 M(-8.8%) |
| Dec 2005 | -$28.15 M(+35.1%) | -$7.41 M(+14.7%) | -$27.39 M(-2.0%) |
| Sep 2005 | - | -$6.46 M(-1.8%) | -$27.95 M(+0.9%) |
| Jun 2005 | - | -$6.58 M(-5.1%) | -$27.69 M(+13.5%) |
| Mar 2005 | - | -$6.94 M(-13.0%) | -$24.41 M(+19.1%) |
| Dec 2004 | -$20.83 M(+111.9%) | -$7.97 M(+28.5%) | -$20.50 M(+18.3%) |
| Sep 2004 | - | -$6.20 M(+88.4%) | -$17.32 M(+16.0%) |
| Jun 2004 | - | -$3.29 M(+8.8%) | -$14.94 M(+113.1%) |
| Mar 2004 | - | -$3.03 M(-36.9%) | -$7.01 M(+0.6%) |
| Dec 2003 | -$9.83 M(+1040.3%) | -$4.79 M(+25.5%) | -$6.97 M(+40.3%) |
| Sep 2003 | - | -$3.82 M(-182.5%) | -$4.97 M(-803.0%) |
| Jun 2003 | - | $4.63 M(-255.1%) | $706.50 K(-148.6%) |
| Mar 2003 | - | -$2.99 M(+7.0%) | -$1.45 M(+97.4%) |
| Dec 2002 | -$862.00 K(-88.0%) | -$2.79 M(-250.8%) | -$736.90 K(-135.9%) |
| Sep 2002 | - | $1.85 M(-25.1%) | $2.06 M(-197.5%) |
| Jun 2002 | - | $2.47 M(-209.0%) | -$2.11 M(-72.8%) |
| Mar 2002 | - | -$2.27 M(-1.8%) | -$7.76 M(-24.2%) |
| Dec 2001 | -$7.20 M(+13.7%) | - | - |
| Aug 2001 | - | -$2.31 M(-27.4%) | -$10.23 M(+9.5%) |
| May 2001 | - | -$3.18 M(+42.3%) | -$9.35 M(+19.3%) |
| Feb 2001 | - | -$2.24 M(-10.7%) | -$7.84 M(+23.2%) |
| Nov 2000 | -$6.33 M(+482.5%) | -$2.50 M(+75.6%) | -$6.36 M(+44.3%) |
| Aug 2000 | - | -$1.43 M(-14.5%) | -$4.40 M(+47.9%) |
| May 2000 | - | -$1.67 M(+120.1%) | -$2.98 M(+73.7%) |
| Feb 2000 | - | -$758.10 K(+37.5%) | -$1.71 M(+57.4%) |
| Nov 1999 | -$1.09 M(-44.4%) | -$551.30 K(<-9900.0%) | -$1.09 M(+102.5%) |
| Aug 1999 | - | $0.00(-100.0%) | -$538.00 K(0.0%) |
| May 1999 | - | -$405.40 K(+205.7%) | -$538.00 K(+305.7%) |
| Feb 1999 | - | -$132.60 K | -$132.60 K |
| Nov 1998 | -$1.95 M | - | - |
FAQ
- What is Aurinia Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals annual EBITDA year-on-year change?
- What is Aurinia Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Aurinia Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals TTM EBITDA year-on-year change?
What is Aurinia Pharmaceuticals annual EBITDA?
The current annual EBITDA of AUPH is -$63.05 M
What is the all time high annual EBITDA for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high annual EBITDA is -$862.00 K
What is Aurinia Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, AUPH annual EBITDA has changed by +$40.60 M (+39.17%)
What is Aurinia Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of AUPH is $20.91 M
What is the all time high quarterly EBITDA for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high quarterly EBITDA is $20.91 M
What is Aurinia Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, AUPH quarterly EBITDA has changed by +$13.39 M (+178.07%)
What is Aurinia Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of AUPH is $4.39 M
What is the all time high TTM EBITDA for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high TTM EBITDA is $6.31 M
What is Aurinia Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, AUPH TTM EBITDA has changed by +$27.39 M (+119.08%)